Verona Pharma PLC Result of AGM (3537C)

TIDMVRP

RNS Number : 3537C

Verona Pharma PLC

12 April 2017

Verona Pharma plc

("Verona Pharma" or the "Company")

Result of AGM

12 April 2017, London - Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announces that all resolutions proposed at the Annual General Meeting (AGM) held today were duly passed.

- End -

For further information, please contact:

 
Verona Pharma plc                     Tel: +44 (0)20 3283 
                                       4200 
Jan-Anders Karlsson, Chief Executive  info@veronapharma.com 
 Officer 
 
N+1 Singer (Nominated Adviser         Tel: +44 (0)20 7496 
 and UK Broker)                        3000 
Aubrey Powell / James White 
 
FTI Consulting (UK Media and          Tel: +44 (0)20 3727 
 Investor enquiries)                   1000 
Simon Conway / Stephanie Cuthbert     veronapharma@fticonsulting.com 
 / 
 Natalie Garland-Collins 
 
ICR, Inc. (US Media and Investor 
 enquiries) 
James Heins                           Tel: +1 203-682-8251 
                                       James.Heins@icrinc.com 
Stephanie Carrington                  Tel. +1 646-277-1282 
                                       Stephanie.Carrington@icrinc.com

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.

Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti--inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGITMTTMBBBBRR

(END) Dow Jones Newswires

April 12, 2017 08:19 ET (12:19 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024